Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effect of ADCC-enhancing mutations on N-glycan profiles of human IgG1 antibodies.

The Biochemical journal - 6 May 2026

Han Lu, Jiang Hao, Chiu Mark L

Abstract excerpt

Human antibody-based therapeutics display characteristic N-glycan profiles that are critical determinants of developability, safety, pharmacokinetics, and efficacy. Although fragment crystallizable (Fc) engineering strategies to modulate effector functions are well established, comparatively less is known about how Fc mutations designed to enhance Fc effector functions, such as antibody-dependent cellular...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibody-Dependent Cell Cytotoxicity
Share to CHO Cells
Share to Cricetinae

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cricetulus

Share to Glycosylation

Share to Immunoglobulin Fc Fragments

Share to Immunoglobulin G

Share to Polysaccharides

Source

Open in PubMed Open full text

Identifiers

PMID: 41873859
DOI: 10.1042/BCJ20253380
PMCID: PMC13142930

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effect of ADCC-enhancing mutations on N-glycan profiles of human IgG1 antibodies.PMID 41873859Read ↗

The interplay of protein engineering and glycoengineering to fine-tune antibody glycosylation and its impact on effector functions.Semantic proximity Read ↗

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector ActivitiesSemantic proximity Read ↗

Profiling the Biophysical Developability Properties of Common IgG1 Fc Effector Silencing VariantsSemantic proximity Read ↗

Asymmetrical Fc engineering greatly enhances antibody-dependent cellular cytotoxicity (ADCC) effector function and stability of the modified antibodies.Semantic proximity Read ↗

Cell-based production of Fc-GlcNAc and Fc-alpha-2,6 sialyl glycan enriched antibody with improved effector functions through glycosylation pathway engineeringSemantic proximity Read ↗

Optimizing therapeutic antibody function: progress with Fc domain engineering.Semantic proximity Read ↗

Engineered antibody Fc variants with enhanced effector function.Semantic proximity Read ↗

Directed Evolution of Therapeutic Antibodies Targeting Glycosylation in CancerSemantic proximity Read ↗

Identification of Engineered IMGT Fc Variants in IMGT/mAb-DB Therapeutic Antibodies and Fusion proteinsSemantic proximity Read ↗

Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potencySemantic proximity Read ↗

Improved Effector Functions of a Therapeutic Monoclonal Lewis Y-Specific Antibody by Glycoform EngineeringSemantic proximity Read ↗

IgG N-glycan Signatures as Potential Diagnostic and Prognostic BiomarkersSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.